Robert J. Anders

1.6k total citations
26 papers, 1.2k citations indexed

About

Robert J. Anders is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pharmacology. According to data from OpenAlex, Robert J. Anders has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 11 papers in Surgery and 3 papers in Pharmacology. Recurrent topics in Robert J. Anders's work include Antiplatelet Therapy and Cardiovascular Diseases (9 papers), Acute Myocardial Infarction Research (8 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (6 papers). Robert J. Anders is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (9 papers), Acute Myocardial Infarction Research (8 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (6 papers). Robert J. Anders collaborates with scholars based in United States, United Kingdom and Canada. Robert J. Anders's co-authors include John C. Alexander, William B. White, Gary Hantsbarger, Neal S. Kleiman, John Paul Runyon, Dean J. Kereiakes, Jay H. Kleiman, Carolyn H. McCabe, Anatoly Langer and Andrew Charlesworth and has published in prestigious journals such as Nature, New England Journal of Medicine and Circulation.

In The Last Decade

Robert J. Anders

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Anders United States	16	905	431	170	152	126	26	1.2k
Daniel D. Gretler United States	20	1.1k 1.2×	441 1.0×	278 1.6×	387 2.5×	52 0.4×	43	1.6k
Ronan J. Curtin United States	15	998 1.1×	331 0.8×	55 0.3×	108 0.7×	157 1.2×	33	1.3k
Kazuteru Fujimoto Japan	15	626 0.7×	256 0.6×	50 0.3×	44 0.3×	109 0.9×	36	1.1k
Keith Finnie Canada	7	747 0.8×	343 0.8×	51 0.3×	207 1.4×	54 0.4×	9	970
Carlo Lavalle Italy	19	887 1.0×	218 0.5×	54 0.3×	70 0.5×	124 1.0×	112	1.3k
Lawson McDonald United Kingdom	16	474 0.5×	225 0.5×	92 0.5×	73 0.5×	200 1.6×	32	1.0k
Brian J. Sealey Canada	10	1.1k 1.2×	462 1.1×	64 0.4×	300 2.0×	83 0.7×	14	1.3k
Zuzana Moťovská Czechia	16	1.1k 1.2×	606 1.4×	41 0.2×	199 1.3×	48 0.4×	89	1.3k
Libardo J. Meléndez Canada	6	797 0.9×	290 0.7×	48 0.3×	188 1.2×	58 0.5×	8	930
Casper H. Jørgensen Denmark	12	627 0.7×	186 0.4×	61 0.4×	165 1.1×	48 0.4×	19	1.4k

Countries citing papers authored by Robert J. Anders

Since Specialization

Citations

This map shows the geographic impact of Robert J. Anders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Anders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Anders more than expected).

Fields of papers citing papers by Robert J. Anders

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Anders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Anders. The network helps show where Robert J. Anders may publish in the future.

Co-authorship network of co-authors of Robert J. Anders

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Anders. A scholar is included among the top collaborators of Robert J. Anders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Anders. Robert J. Anders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takaya, Norihide, Jianming Cai, Marina S. Ferguson, et al.. (2006). Intra‐ and interreader reproducibility of magnetic resonance imaging for quantifying the lipid‐rich necrotic core is improved with gadolinium contrast enhancement. Journal of Magnetic Resonance Imaging. 24(1). 203–210. 81 indexed citations

Vaitkus, Paul T., et al.. (2003). Early heightened inflammation promotes greater left ventricular remodeling following anterior myocardial infarction. Journal of the American College of Cardiology. 41(6). 194–194.

Serrano, Carlos, José Carlos Nicolau, Margareth L. Venturinelli, et al.. (2003). Role of Oral Blockade of Platelet Glycoprotein IIb/IIIa on Neutrophil Activation in Patients with Acute Coronary Syndromes. Cardiovascular Drugs and Therapy. 17(2). 129–132. 6 indexed citations

Bakris, George L., et al.. (2002). A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. American Journal of Hypertension. 15(1). 53–57. 35 indexed citations

White, William B., Domenic A. Sica, David A. Calhoun, George A. Mansoor, & Robert J. Anders. (2002). Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. American Heart Journal. 144(4). 657–665. 37 indexed citations

Anders, Robert J., et al.. (2001). Xemilofiban/Orbofiban: Insight into Drug Development. Cardiovascular Drug Reviews. 19(2). 116–132. 18 indexed citations

Nicholson, Nancy S., Susan G. Panzer‐Knodle, Jimmy D. Page, et al.. (2001). Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist. Medicinal Research Reviews. 21(3). 211–226. 22 indexed citations

White, William B., Mary F. Johnson, Robert J. Anders, W.J. Elliott, & Henry R. Black. (2001). Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. American Heart Journal. 142(6). 1010–1015. 19 indexed citations

Black, Henry R., W.J. Elliott, James D. Neaton, et al.. (2001). Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension. 37(1). 12–18. 159 indexed citations

10.

O’Neill, William W., Patrick W. Serruys, M.L. Knudtson, et al.. (2000). Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization. New England Journal of Medicine. 342(18). 1316–1324. 156 indexed citations

11.

O’Neill, William W., Patrick W. Serruys, M.L. Knudtson, et al.. (1999). Design and Objectives of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) Study. Journal of Interventional Cardiology. 12(2). 109–116. 4 indexed citations

12.

Kereiakes, Dean J., Neal S. Kleiman, James J. Ferguson, et al.. (1998). Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban. Circulation. 98(13). 1268–1278. 81 indexed citations

13.

Simpfendorfer, Conrad, Kandice Kottke‐Marchant, Robert J. Anders, et al.. (1997). First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade. Circulation. 96(1). 76–81. 98 indexed citations

14.

Neutel, Joel M., Michael H. Alderman, Robert J. Anders, & Michael A. Weber. (1996). Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. American Heart Journal. 132(6). 1202–1206. 20 indexed citations

15.

Anders, Robert J., Stanford S. Jhee, John J. Sramek, et al.. (1995). Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. The American Journal of Cardiology. 75(16). 1102–1106. 35 indexed citations

16.

Anders, Robert J., John C. Alexander, Gary Hantsbarger, et al.. (1995). 931-113 Demonstration of Potent Inhibition of Platelet Aggregation with an Orally Active GPllb/IIIA Receptor Antagonist. Journal of the American College of Cardiology. 25(2). 117A–117A. 8 indexed citations

17.

Rabito, Sara F., et al.. (1992). Carboxypeptidase N concentration during cardiopulmonary bypass in humans. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 39(1). 54–59. 4 indexed citations

18.

Anders, Robert J., Alan H. Lau, Roohollah Sharifi, & Mary Lee. (1987). Comparison of EMIT Versus Bioassay to Evaluate Inactivation of Tobramycin by Piperacillin. Therapeutic Drug Monitoring. 9(4). 472–477. 4 indexed citations

19.

Dasta, Joseph F., et al.. (1986). Compatibility of Intravenous Drugs in a Coronary Intensive Care Unit. Drug Intelligence & Clinical Pharmacy. 20(5). 349–352. 5 indexed citations

20.

Anders, Robert J., et al.. (1986). Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low-dose administration. American Heart Journal. 111(4). 755–759. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact